159 related articles for article (PubMed ID: 29250656)
21. Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas.
Masjeed NMA; Khandeparkar SGS; Joshi AR; Kulkarni MM; Pandya N
J Clin Diagn Res; 2017 Aug; 11(8):EC31-EC34. PubMed ID: 28969139
[TBL] [Abstract][Full Text] [Related]
22. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
23. Supervised clustering of immunohistochemical markers to distinguish atypical and non-atypical endometrial hyperplasia.
Laas E; Ballester M; Cortez A; Gonin J; Canlorbe G; Daraï E; Graesslin O
Gynecol Endocrinol; 2015 Apr; 31(4):282-5. PubMed ID: 25495249
[TBL] [Abstract][Full Text] [Related]
24. Analysis of PTEN, estrogen receptor α and progesterone receptor expression in endometrial hyperplasia using tissue microarray.
Pieczyńska B; Wojtylak S; Zawrocki A; Biernat W
Pol J Pathol; 2011 Sep; 62(3):133-8. PubMed ID: 22102068
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma.
Chakravarty D; Srinivasan R; Ghosh S; Rajwanshi A; Gopalan S
Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):535-42. PubMed ID: 18931615
[TBL] [Abstract][Full Text] [Related]
26. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma.
Kendall BS; Ronnett BM; Isacson C; Cho KR; Hedrick L; Diener-West M; Kurman RJ
Am J Surg Pathol; 1998 Aug; 22(8):1012-9. PubMed ID: 9706982
[TBL] [Abstract][Full Text] [Related]
27. Expression and clinical significance of ghrelin in endometrial hyperplasia and carcinoma of Egyptian patients.
Younes SF; Aiad H; Kandil M; El Kalashy FS
Ultrastruct Pathol; 2015 May; 39(3):207-13. PubMed ID: 25569277
[TBL] [Abstract][Full Text] [Related]
28. Patterns of immunohistochemical staining for p53 expression in hyperplastic endometrium and adenocarcinoma.
Terlikowski S; Lenczewski A; Famulski W; Sulkowska M; Dobrzycka B; Stasiuk-Barmuta A; Kulikowski M
Folia Histochem Cytobiol; 2001; 39 Suppl 2():195-6. PubMed ID: 11820604
[TBL] [Abstract][Full Text] [Related]
29. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Campanino MR; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):275-286. PubMed ID: 30511743
[TBL] [Abstract][Full Text] [Related]
30. Endometrial hyperplasia-related inflammation: its role in the development and progression of endometrial hyperplasia.
Kubyshkin AV; Aliev LL; Fomochkina II; Kovalenko YP; Litvinova SV; Filonenko TG; Lomakin NV; Kubyshkin VA; Karapetian OV
Inflamm Res; 2016 Oct; 65(10):785-94. PubMed ID: 27312112
[TBL] [Abstract][Full Text] [Related]
31. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.
Ashton-Sager A; Paulino AF; Afify AM
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):187-92. PubMed ID: 16785788
[TBL] [Abstract][Full Text] [Related]
32. Maspin expression, subcellular localization and clinicopathological correlation in endometrial hyperplasia and endometrial adenocarcinoma.
Blandamura S; Alessandrini L; Saccardi C; Giacomelli L; Fabris A; Borghero A; Litta P
Histol Histopathol; 2014 Jun; 29(6):777-83. PubMed ID: 24346847
[TBL] [Abstract][Full Text] [Related]
33. PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma.
Pavlakis K; Messini I; Vrekoussis T; Panoskaltsis T; Chrissanthakis D; Yiannou P; Stathopoulos EN
Gynecol Oncol; 2010 Dec; 119(3):516-9. PubMed ID: 20833413
[TBL] [Abstract][Full Text] [Related]
34. Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases.
Němejcová K; Rosmusová J; Bártů M; Důra M; Tichá I; Dundr P
Int J Surg Pathol; 2017 Aug; 25(5):389-396. PubMed ID: 28381136
[TBL] [Abstract][Full Text] [Related]
35. Determining the inter- and intraobserver reproducibility of the diagnosis of endometrial hyperplasia subgroups and well-differentiated endometrioid carcinoma in endometrial curettage specimens.
Izadi-Mood N; Khaniki M; Irvanloo G; Ahmadi SA; Hayeri H; Meysamie A
Arch Iran Med; 2009 Jul; 12(4):377-82. PubMed ID: 19566355
[TBL] [Abstract][Full Text] [Related]
36. PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer?
Travaglino A; Raffone A; Saccone G; Mascolo M; Pignatiello S; Mollo A; De Placido G; Insabato L; Zullo F
APMIS; 2019 Apr; 127(4):161-169. PubMed ID: 30803040
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women.
Norimatsu Y; Moriya T; Kobayashi TK; Sakurai T; Shimizu K; Tsukayama C; Ohno E
Ann Diagn Pathol; 2007 Apr; 11(2):103-8. PubMed ID: 17349568
[TBL] [Abstract][Full Text] [Related]
38. PROLIFERATIVE/STEM CELL INDEX AND PHENOTYPIC CHARACTERISTICS OF PROLIFERATIVE PROCESSES IN ENDOMETRIUM.
Kikalishvili N; Beriashvili R; Muzashvili T; Burkadze G
Georgian Med News; 2018 Sep; (282):156-161. PubMed ID: 30358561
[TBL] [Abstract][Full Text] [Related]
39. Utility of p63 and PTEN staining in distinguishing cervical microglandular hyperplasia from endometrial endometrioid carcinoma with microglandular/mucinous features.
Aoun BA; Skala SL
Histopathology; 2022 Jun; 80(7):1102-1111. PubMed ID: 35347751
[TBL] [Abstract][Full Text] [Related]
40. [Endometrial hyperplasia, diagnosis. Clinical, paraclinical exam and management].
Pangal A; Costăchescu G; Aldea MJ
Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):445-9. PubMed ID: 20700983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
